QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design – Hagens Berman

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Investor rights law firm Hagens Berman reminds investors in uniQure N.V. (NASDAQ: QURE) that the Lead Plaintiff Deadline in litigation against the company and certain of its executives is rapidly approaching: April 13, 2026. The lawsuit alleges that the defendants made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130, specifically concerning the FDA’s acceptance of a “pivotal” study design that o ...